Adding trotabresib to chemoradiotherapy did not improve progression-free or overall survival and was associated with more dose reductions and interruptions.
|Slideshows|May 30, 2017
10 Tricks for Surviving and Thriving at ASCO’s Annual Meeting
This slide show presents tricks for surviving and thriving at the ASCO Annual Meeting in Chicago. Everything from transportation, McCormick Place, planning your days, using social media, which sessions to attend, how to network, where to eat, and how to be a tourist in Chicago.
Advertisement
Advertisement
Related to this article
Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed quadruplet induction, extended maintenance, and when a community clinician should call a myeloma center.
Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed the threshold he will act on in standard-risk disease, and the trial that would make the decision firmer.
Daniel Y.C. Heng, MD, MPH, FRCPC, explained how he manages anemia, hypoxia, and cardiac toxicity with belzutifan plus lenvatinib for renal cell carcinoma.
Daniel Y.C. Heng, MD, MPH, FRCPC, discussed final LITESPARK-011 data, toxicity management, and treatment sequencing in advanced renal cell carcinoma.
In a retrospective analysis, teclistamab produced response rates numerically higher than in MajesTEC-1, with missed doses not compromising outcomes.
Neil Mehta, MD, and Laura Kulik, MD, discussed which patients with HCC awaiting liver transplant may benefit from bridging immunotherapy.
Ryosuke Tateishi, MD, PhD, discussed lifestyle interventions, surveillance, and what the US and Japan can share to prevent MASLD-related liver cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Perioperative Durvalumab/Enfortumab Vedotin in MIBC
2
Anthracycline Chemo May Accelerate Biological Aging in Breast Cancer Survivors
3
What Sustained MRD Negativity Can Settle About Stopping Myeloma Maintenance
4
Survival in Childhood and Adolescent Cancers Improves, but Racial Disparities Persist
5